Jaime Grund: Thrilled to welcome Mollie Beck to the Precision Medicine team

Jaime Grund shared a post on LinkedIn:

“We are thrilled to welcome Mollie Beck, PharmD, BCOP to the Precision Medicine team! As our Precision Oncology Therapeutic specialist, Mollie’s addition to the program is a game changer for oncology care in NKY and IN.

I am continually in awe of the brilliant minds who are eager to dedicate their talents to provide genomically driven care to the patients of St. Elizabeth Healthcare. Every single person in this group photo (and those who missed the photo op) are absolutely vital to our team.”

Douglas Flora shared this post, adding:

“Great to see this program continue to grow. Grateful to be in a place that invests in innovation and sees the value in Precision Medicine.

Welcome aboard, Dr.Beck! We’ve been waiting for you! Excited to see what you do next.”

Source: Jaime Grund/LinkedIn and Douglas Flora/LinkedIn

Jaime Grund, LGC, is the Director of Precision Medicine and Breast Centers at St. Elizabeth Healthcare, KY. With twenty years of experience, she founded the Department of Precision Medicine in 2018, which now offers services in precision oncology, pharmacogenomics, hereditary cancer prevention, cardiovascular genetics, and perinatal screening.

Mollie Beck is a Precision Oncology Therapeutic Specialist at St. Elizabeth Healthcare. In her role, she focuses on integrating precision medicine approaches into oncology treatment plans, ensuring that therapies are tailored to the genetic profile of each patient’s cancer.

Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine; Genomic Health.

As the Editor-in-Chief of ‘AI in Precision Oncology,’ the first peer-reviewed academic journal dedicated to this field, he plays a pivotal role in advancing research. He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.